Related Experiment Video

Updated: Aug 24, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

[New pneumococcal vaccine]

Joël Gaudelus1

  • 1Service de Pédiatrie-CHU Jean Verdier-93140 Bondy.

Bulletin De L'Academie Nationale De Medecine
|May 19, 2004
PubMed

Insights

The heptavalent pneumococcal vaccine (PCV) is safe and highly effective against invasive pneumococcal diseases in infants, significantly reducing pneumonia incidence. Its efficacy against acute otitis media is limited, suggesting broader French indications may be warranted.

Area of Science:

  • Pediatric infectious diseases
  • Vaccinology
  • Bacteriology

Context:

  • Streptococcus pneumoniae is a leading cause of invasive bacterial infections in children under two.
  • Invasive pneumococcal diseases include bacteremia and meningitis.
  • The heptavalent pneumococcal conjugate vaccine (PCV) targets seven key serotypes.

Purpose:

  • To evaluate the safety, immunogenicity, and efficacy of the heptavalent pneumococcal conjugate vaccine (PCV) in infants.
  • To assess PCV's impact on invasive pneumococcal diseases, pneumonia, and acute otitis media.
  • To inform potential extensions of French vaccine indications.

Summary:

  • The PCV vaccine is well-tolerated, immunogenic, and demonstrates over 95% efficacy in preventing invasive pneumococcal diseases.
  • Significant reductions in pneumonia incidence were observed: 32.2% in the first year and 23.4% in the first two years post-vaccination.
  • Efficacy against acute otitis media was found to be poor.

Impact:

  • The PCV vaccine represents a major advancement in preventing serious childhood infections.
  • Current French indications are limited to high-risk infants under two.
  • Evidence supports extending PCV vaccination to all infants under two years of age for broader protection.

More Related Videos

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Streptococcal Pharyngitis01:27

Streptococcal Pharyngitis

Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: